Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients

International Journal of Cardiovascular Imaging

Volumn 28, Issue 7, 2012, Pages 1841-1849

  Husain, Zehra ^a   Palani, Gurunanthan ^b   Cabrera, Rafael ^c   Karthikeyan, Aarthee S ^c   Dhanalakota, Sunitha ^c   Pathmanathan, Suba ^c   Jacobsen, Gordon ^c   Ananthasubramaniam, Karthik ^c  

^a ST JOSEPH MERCY OAKLAND HOSPITAL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Asthma; Bronchospasm; Chronic obstructive pulmonary disease; Regadenoson; Side effects; Single photon emission computed tomography

Indexed keywords

ADENOSINE; DIPYRIDAMOLE; REGADENOSON; TETROFOSMIN TC 99M; THALLIUM;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHOSPASM; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DYSPNEA; FEMALE; HEADACHE; HEART RATE VARIABILITY; HEMODYNAMIC MONITORING; HOSPITALIZATION; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOCARDIAL PERFUSION IMAGING; PATIENT SAFETY; PHARMACOLOGIC STRESS TESTING; PHYSICAL TOLERANCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; AGED; ASTHMA; ATRIOVENTRICULAR BLOCK; BRONCHOCONSTRICTION; CHI-SQUARE DISTRIBUTION; FEMALE; HEART DISEASES; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PURINES; PYRAZOLES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TACHYCARDIA, SUPRAVENTRICULAR; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASODILATOR AGENTS;

EID: 84870410331     PISSN: 15695794     EISSN: 15730743     Source Type: Journal    
DOI: 10.1007/s10554-011-0003-3     Document Type: Article

References (25)

1. Travin MI, Wexler JP (1999) Pharmacological stress testing. Semin Nucl Med 29:298-318. (Pubitemid 29487498)
2. Shryock JC, Belardinelli L (1997) Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 79:2-10. (Pubitemid 27305162)
3. Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS (1994) Safety profile of adenosine stress perfusion imaging: results from the adenoscan multicenter trial registry. J Am Coll Cardiol 23:384-389. (Pubitemid 24049369)
4. Johnston DL, Daley JR, Hodge DO, Hopfenspirger MR, Gibbons RJ (1995) Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stress testing: a comparison in 2000 patients. Mayo Clin Proc 70:331-336.
5. Ranhosky A, Kempthorne-Rawson J (1990) The safety of intravenous dipyridamole thallium myocardial perfusion imaging: intravenous dipyridamole thallium imaging study group. Circulation 81:1205-1209. (Pubitemid 20119617)
6. Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, Feoktistov I (2004) Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2b mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 172:7726-7733. (Pubitemid 38747640)
7. Feoktistov I, Biaggioni I (1996) Role of adenosine in asthma. Drug Dev Res 39:333-336. (Pubitemid 27199343)
8. Feoktistov I, Polosa R, Holgate ST, Biaggioni I (1998) Adenosine A2b receptors: a novel therapeutic target in asthma? Trends Pharmacol Sci 19:148-153. (Pubitemid 28218538)
9. Fan M, Qin W, Mustafa SJ (2003) Characterisation of adenosine receptors involved in adenosine-induced bronchoconstriction in an allergic mouse model. Am J Physiol Lung Cell Mol Physiol 284:L1012-L1019. (Pubitemid 36687137)
10. Garnock-Jones KP, Curran MP (2010) Regadenoson. Am J Cardiovasc Drugs 10:65-71.
11. Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzein E, Palle V, Zablocki JA, Blackburn B, Belardinelli L (2001) Novel short-acting A2a adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2a agonists. J Pharmacol Exp Ther 298:209-218. (Pubitemid 32574529)
12. Henzlova MJ, Cerqueira MD, Hansen CL, Taillefer R, Yao S (2009) American society of nuclear cardiology. ASNC imaging guidelines for nuclear cardiology procedures: stress protocols and tracers. J Nucl Cardiol 16:331.
13. Geleijnse ML, Elhendy A, Fioretti PM, Roelandt JR (2000) Dobutamine stress myocardial perfusion imaging. J Am Coll Cardiol 36:2017-2027.
14. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, Mathur V (2008) Safety of regadenoson, a selective adenosine A2a agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 15:319-328.
15. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, Lieu HD (2008) Safety of regadenoson, an adenosine A2a receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 15:329-336.
16. Reyes E, Loong CY, Wechalekar K, Latus K, Anagnostopoulos C, Underwood SR (2007) Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 14:827-834. (Pubitemid 350082577)
17. Shaffer J, Simbartl L, Render ML, Snow E, Chaney C, Nishiyama H, Rauf GC, Wexler LF (1998) Patients with stable chronic obstructive pulmonary disease can safely undergo intravenous dipyridamole thallium-201 imaging. Am Heart J 136:307-313. (Pubitemid 28368855)
18. Holly TA, Abbott BG, Al-Mallah M, et al (2010) ASNC imaging guidelines for nuclear cardiology procedures: single photon-emission computed tomography. J Nucl Cardiol 17:941-973. doi:10.1007/s12350-010-9246-y.
19. Dhalla AK, Wong MY, Wanh WQ, Biaggioni I, Belardinelli L (2006) Tachycardia caused by A2a adenosine receptor agonists is mediated by directsympathoexcitation in awake rats. J Pharmacol Exp Ther 316:695-702. (Pubitemid 43130996)
20. Seshadri N, Gildea TR, McCarthy K, Pothier C, Kavuru MS, Lauer MS (2004) Association of an abnormal exercise HR recovery with pulmonary function abnormalities. Chest 125:1286-1291. (Pubitemid 38501340)
21. Shih HT, Webb CR, Conway WA, Peterson E, Tilley B, Goldstein S (1988) Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. Chest 94:44-48.
22. Cerqueira MD (2004) The future of pharmacologic stress: selective A2a adenosine receptor agonists. Am J Cardiol 94:33D-40D; discussion 40D-42D.
23. Balan KK, Critchley M (2001) Is the dyspnea during adenosine cardiac stress test caused by bronchospasm? Am Heart J 142:142-145. (Pubitemid 32595386)
24. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE (2008) Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 1:307-316. (Pubitemid 351676842)
25. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, Moye LA, Olmsted AW (2009) Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2:959-968.